Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer: A Multicenter Real-World Study

NCT06926179 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT06926179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06926179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer: A Multicenter Real-World Study
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Observational
Overall status
Recruiting
Start date
December 1, 2024
Completion date
March 31, 2028
Enrollment
500 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc), lung surgery, neoadjuvant immunotherapy, radiotherapy